Suggested remit - To appraise the clinical and cost effectiveness of galcanezumab within its marketing authorisation for preventing migraine.
Status Proposed
Process STA 2018
ID number 1372

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
10 September 2019 The Department for Health and Social Care has asked us to carry out a Single Technology Appraisal of galcanezumab for preventing migraine. The appraisal is expected to start in approximately late November 2019 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE until after the anticipated marketing authorisation has been received, in order to facilitate a suitably comprehensive and robust evidence submission.
28 January 2019 - 25 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance